TY - JOUR
T1 - Comparison of ultrasound- versus fluoroscopy-guidEd femorAl access In tranS-catheter aortic valve replacement In the Era of contempoRary devices: The EASIER registry
AU - Bianchini, Emiliano
AU - Morello, Alberto
AU - Bellamoli, Michele
AU - Romagnoli, Enrico
AU - Aurigemma, Cristina
AU - Tagliaferri, Marco
AU - Montonati, Carolina
AU - Dumonteil, Nicolas
AU - Cimmino, Michele
AU - Villa, Emmanuel
AU - Corcione, Nicola
AU - Bettari, Luca
AU - Messina, Antonio
AU - Stanzione, Alessio
AU - Troise, Giovanni
AU - Mor, Donata
AU - Maggi, Antonio
AU - Bellosta, Raffaello
AU - Pegorer, Matteo Alberto
AU - Zoccai, Giuseppe Biondi
AU - Ielasi, Alfonso
AU - Burzotta, Francesco
AU - Trani, Carlo
AU - Maffeo, Diego
AU - Tchétché, Didier
AU - Buono, Andrea
AU - Giordano, Arturo
PY - 2024
Y1 - 2024
N2 - Background: Vascular complications (VCs) still represent one of the principal concerns of trans-femoral trans-catheter aortic valve replacement (TF-TAVR). New-generation devices can minimize such complications but the arterial access management is left to the operator's choice. This study aims to describe the rate of VCs in a contemporary cohort of patients undergoing TAVR with new-generation devices and to determine whether an ultrasound-guided (USG) vs. a fluoroscopy-guided (FG) femoral access management has an impact on their prevention. Methods: This is a prospective, observational, multicenter study. Consecutive patients undergoing TAVR with new-generation devices were analyzed from January 2022 to October 2022 in five tertiary care centers. Femoral accesses were managed according to the operator's preferences. All the patients underwent a pre-discharge peripheral ultrasound control. VCs and bleedings were the main endpoints of interest. Results: A total of 458 consecutive patients were enrolled (274 in the USG group and 184 in the FG group). VCs occurred in 6.5 % of the patients (5.2 % minor and 1.3 % major). There was no difference between the USG and the FG groups in terms of any VCs (7.3 % vs. 5.4 %; p = 0.4), or any VARC-3 bleedings (6.9 % vs 6 %, p = 0.9). At logistic regression analysis, the two guidance strategies did not result as predictors of VCs (odds Ratio 0.8, 95 % Confidence Interval 0.46-1.4; P = 0.4). Conclusions: In a contemporary cohort of patients undergoing TAVR with new-generation devices, the occurrence of VCs is low and mostly represented by minor VCs. USG and FG modalities did not affect the rate of VCs.
AB - Background: Vascular complications (VCs) still represent one of the principal concerns of trans-femoral trans-catheter aortic valve replacement (TF-TAVR). New-generation devices can minimize such complications but the arterial access management is left to the operator's choice. This study aims to describe the rate of VCs in a contemporary cohort of patients undergoing TAVR with new-generation devices and to determine whether an ultrasound-guided (USG) vs. a fluoroscopy-guided (FG) femoral access management has an impact on their prevention. Methods: This is a prospective, observational, multicenter study. Consecutive patients undergoing TAVR with new-generation devices were analyzed from January 2022 to October 2022 in five tertiary care centers. Femoral accesses were managed according to the operator's preferences. All the patients underwent a pre-discharge peripheral ultrasound control. VCs and bleedings were the main endpoints of interest. Results: A total of 458 consecutive patients were enrolled (274 in the USG group and 184 in the FG group). VCs occurred in 6.5 % of the patients (5.2 % minor and 1.3 % major). There was no difference between the USG and the FG groups in terms of any VCs (7.3 % vs. 5.4 %; p = 0.4), or any VARC-3 bleedings (6.9 % vs 6 %, p = 0.9). At logistic regression analysis, the two guidance strategies did not result as predictors of VCs (odds Ratio 0.8, 95 % Confidence Interval 0.46-1.4; P = 0.4). Conclusions: In a contemporary cohort of patients undergoing TAVR with new-generation devices, the occurrence of VCs is low and mostly represented by minor VCs. USG and FG modalities did not affect the rate of VCs.
KW - Femoral access management
KW - Fluoroscopy
KW - Puncture guidance
KW - TAVR
KW - Ultrasound
KW - Vascular complication
KW - Femoral access management
KW - Fluoroscopy
KW - Puncture guidance
KW - TAVR
KW - Ultrasound
KW - Vascular complication
UR - https://publicatt.unicatt.it/handle/10807/260618
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85180577473&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85180577473&origin=inward
U2 - 10.1016/j.carrev.2023.12.007
DO - 10.1016/j.carrev.2023.12.007
M3 - Article
SN - 1553-8389
SP - 40
EP - 47
JO - Cardiovascular Revascularization Medicine
JF - Cardiovascular Revascularization Medicine
IS - 62
ER -